Kintor Pharmaceutical Announces Results from Investigator-Initiated Brazil Trial Demonstrating 92% Reduction in Mortality in Hospitalized COVID-19 Patients
Share this article Share this article SUZHOU, China, March 11, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX: 9939), a clinical-stage biotechnology company developing small molecule and biological therapeutics, announced today top-line results from its investigator-initiated Brazil trial evaluating the efficacy of Proxalutamide relative to standard of care as assessed by the COVID-19 ordinal scale. In the clinical trial, Proxalutamide met the primary endpoint at day 14, demons...
Source: prnewswire.com